主要学术成就： 主要临床和研究方向为乳腺癌外科治疗，综合治疗，及分子亚型基础转化研究。 国家杰出青年基金获得者（2023），国家优秀青年基金获得者（2017）。擅长乳腺癌手术治疗，精于多学科综合治疗和局部晚期乳腺癌诊治。累计主刀乳腺癌手术10000余例，重视并开展乳腺癌新技术，其中保乳手术占恶性手术量30%，前哨淋巴结活检占80%，乳房重建占20%。每年专家门诊量超过6000例，年收治初诊乳腺癌患者1000例。获上海市青年优秀学术带头人、上海市曙光人才、上海市科技启明星、上海市青年岗位能手、复旦大学卓识人才、卓学人才等称号，及复旦大学五四青年奖章、复旦大学校长奖等奖项。近五年以通讯作者/第一作者在J Clin Oncol（IF=50.7）、JAMA Oncol（IF=33.0）、Adv Sci（IF=17.5）、Nat Commun（IF=17.7）、Cell Rep Med（IF=14.3）、JNCI（IF=11.8）、Sci Adv（IF=15.0）、Cancer Res（IF=13.3）、Clin Cancer Res（IF=13.8）、BMC Med（IF=11.2）、Cancer Commun（IF=15.3）、Clin Transl Med（IF=8.5）、JCI Insight（IF=8.0）、Lancet Reg Health West Pac（IF=8.6）等国际权威SCI期刊上发表论著50余篇，多篇第一作者或通讯作者述评发表于Nat Rev Cancer、J Clin Oncol、JAMA Oncol、Lancet Oncol等上。据Web of Science统计，论文被引用5300余次，H指数为45（有45篇论文分别被引用至少45次以上），成果多次获得省部级科技进步一等奖。 目前担任全球早期乳腺癌试验者协作组（EBCTCG）指导委员会委员；担任Front Oncol期刊Breast Cancer版块副主编，Cancer Med编委，Cancer Biol Med终审专家，为J Clin Invest、JCO、JAMA Oncol、Lancet Oncol、Cancer Res、Breast Cancer Res treat、BMC Cancer、《中国肿瘤临床》、《肿瘤学杂志》等国内外10余家知名学术刊物的同行评审；是国家自然科学基金委、香港研究資助局、澳门科技发展基金会、中国教育部学位与研究生教育发展中心、上海市科委项目评审专家；担任《中国抗癌协会乳腺癌诊治指南与规范》全文版的编撰秘书长，并主持《中国抗癌协会乳腺癌诊治指南与规范》精要版编撰，指南累计继续教育乳腺肿瘤医护人员20000人次，精要版印制推广6万余册，该指南已成为国内最流行的乳腺癌诊治指南和规范之一。主编《精准医学时代的乳腺肿瘤学》（复旦大学出版社，中国 ISBN 978-7-309-12546-7 2016）、副主编《Breast Cancer》（AME Publishing Company, Hong Kong ISBN: 978-988-77841-2-8 2017）。 主持或参加科研项目及人才计划项目情况： 1. 国家杰出青年科学基金, 82325042，乳腺癌进展机制与分型治疗研究，2024/01-2028/12，400万，在研，主持 2. 国家重点研发计划“前沿技术”专项，2023YFC3404100，肿瘤恶性进展关键驱动分子的新型靶向降解系统研发及应用，2023/12-2028/11, 396万，在研，课题负责人 3. 国家重点研发计划“常见多发病防治研究”专项，2023YFC2506400，基于人工智能的免疫制剂肿瘤原位治疗技术体系建立，2023/11-2026/10，76万，在研，项目骨干 4. 上海市教委科研创新计划重大项目，2023-05-50，三阴性乳腺癌HER2-Low亚组的子类鉴定和治疗靶点探索，2023/01-2027/12，300万，在研，主持 5. 国家自然科学基金面上项目，82072916，拷贝数扩增基因ENSA通过与HSP90结合促进LAR型三阴性乳腺癌增殖与耐药的机制研究，2021/01-2024/12，55万元，在研，主持 6. 国家自然科学基金优秀青年科学基金项目, 81722032，三阴性乳腺癌，2018/01-2020/12，130万，已结题，主持 7. 国家自然科学基金面上项目，81672600，长链非编码RNA-SNRPEP4影响三阴性乳腺癌化疗敏感性的机制研究，2017/01-2020/12，57万元，已结题，主持 8. 上海市科委优秀学术带头人，三阴性乳腺癌的临床和转化研究，19XD1420800，2019/01-2021/12，40万，已结题，主持 9. 上海市教育委员会曙光计划项目，2016004，曙光计划人才项目，2016/01-2018/12，15万元，已结题，主持 10. 国家自然科学基金面上项目，81370075，趋化因子诱骗受体DARC通过清除微环境中CCL28抑制MSL型三阴性乳腺癌增殖侵袭的机制研究，2014/01-2017/12，78万元，已结题，主持 11. 国家自然科学基金青年科学基金项目，81001169，揭示微环境中趋化因子Decoy受体的功能性基因多态对乳腺癌转移潜能的影响，2011/01-2013/12，22万元，已结题，主持 12. 上海市国际科技合作基金项目，12410707700，乳腺癌和大肠癌患者自然杀伤细胞相关免疫生物标志物的鉴定，2012/10-2014/09，20万元，已结题，主持 13. 上海市卫生系统优秀人才培养计划，XYQ2013101，优秀青年人才计划，2014/01-2017/01，50万元，已结题，主持 14. 上海市青年科技启明星计划（A类），11QA1401400，科技启明星人才计划，2010/04-2013/04，15万元，已结题，主持 15. 上海市卫生局青年科研项目，2009Y010，应用microRNA基因多态预测乳腺癌的发生风险，2010/01-2012/12，2万元，已结题，主持 省部级以上科研成果奖励 1.2022年中华医学科技三等奖（排名第五；证书号 202103017P0805） 中国三阴性乳腺癌分子分型和精准治疗的研究和成果推广；获奖者：邵志敏、江一舟、李大强、吴炅、余科达、黄薇、胡欣、柳光宇、狄根红、马丁、李俊杰、沈镇宙 2.2021年全国妇幼健康科技成果一等奖（排名第二; 证书号: 2021KJ0102） 三阴性乳腺癌的临床基础研究及含铂方案在其领域的推广应用；获奖者：袁芃、余科达、张剑、杨其峰、宋咏梅、樊英、方仪、李贵、李俏、张频 3.2020年度上海市科技进步一等奖 （排名第五；证书号20204030-1-R05） 中国乳腺癌分子分型和精准治疗的研究和成果推广；获奖者：邵志敏、江一舟、李大强、吴炅、余科达、黄薇、石乐明、胡欣、柳光宇、王中华、狄根红、李俊杰、马丁、肖毅、沈镇宙 4.2020年度中国抗癌协会科技一等奖（排名第四；证书号K-2003-1-2-4） 中国乳腺癌分子分型和精准治疗的研究和成果推广；获奖者：邵志敏、江一舟、李大强、余科达、胡欣、王中华、吴炅、柳光宇、马丁、肖毅 5.2019年上海市抗癌科技奖一等奖 （排名第三：证书号SACA-2019-1A） 中国三阴性乳腺癌分子分型和精准治疗的研究和成果推广；获奖者：邵志敏、江一舟、余科达、黄薇、王中华、吴炅、柳光宇、马丁、胡欣、肖毅 6.2013年度中国抗癌协会科技一等奖（排名第十；证书号K-1303-1-3-10） 提高中国乳腺癌患者早期诊断率和远期生存率的临床和转化研究；获奖者：邵志敏 沈镇宙 胡夕春 郭小毛 吴炅 柳光宇 狄根红 陈佳艺 杨文涛 余科达 7.2011年度上海市科技进步一等奖（排名第三；证书号20114407-1-R03） 基于中国上海乳腺癌流行病学特征的肿瘤筛查和早期诊断模式应用与推广；获奖者：邵志敏 沈镇宙 余科达 柳光宇 吴炅 胡震 曹阿勇 狄根红 陆劲松 欧周罗 金伟 侯意枫 8.2011年度教育部科技进步一等奖（排名第三；证书号2011-209） 乳腺癌社区筛查和早期诊断模式的建立、临床推广和基础研究；获奖者：邵志敏 沈镇宙 余科达 柳光宇 吴炅 胡震 曹阿勇 狄根红 陆劲松 欧周罗 金伟 侯意枫 9.2009年度教育部科技进步一等奖（排名第七；证书号2008-152）乳腺癌肺转移机制的研究和临床应用；获奖者：邵志敏、沈镇宙、欧周罗、吴炅、陆劲松、狄根红、余科达、侯意枫、常新忠、王杰 10.2009年度上海市科技进步二等奖（排名第八；证书号20094152-2-R08） 乳腺癌肺转移调控机制的揭示和临床应用；获奖者：邵志敏 沈镇宙 欧周罗 吴炅 陆劲松 狄根红 侯意枫 余科达 常新忠 王杰 11.2008年中华医学科技三等奖（排名第三；证书号200803095P0808） 乳腺癌转移机制的研究和临床应用；获奖者：邵志敏 沈镇宙 余科达 柳光宇 吴炅 胡震 曹阿勇 狄根红 陆劲松 欧周罗 金伟 侯意枫 近5年发表的部分论文列表（均为通讯/第一作者）： 第一作者# 通讯作者* 1. Liu CC, Chen L, Cai YW, Chen YF, Liu YM, Zhou YJ, Shao ZM, Yu KD*. Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell Rep Med. 2024 Feb 20;5(2):101396. 2. Chen L, Liu CC, Zhu SY, Ge JY, Chen YF, Ma D, Shao ZM, Yu KD*. Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects. JCI Insight. 2023;8(22):e172366. 3. Liu YM, Ge JY, Chen YF, Liu T, Chen L, Liu CC, Ma D, Chen YY, Cai YW, Xu YY, Shao ZM, Yu KD*. Combined Single-Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination. Adv Sci (Weinh). 2023:e2205395. 4. Chen YF, Xu YY, Shao ZM, Yu KD*. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (Lond). 2022. doi: 10.1002/cac2.12387. 5. Cai YW, Shao ZM, Yu KD*. Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis. Front Immunol. 2022;13:919369. 6. Xiao Y, Ding J, Ma D, Chen S, Li X, Yu K. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer. Front Immunol. 2022;13:877825 7. Cai YW, Shao ZM, Yu KD*. De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort. Cancer. 2022;128(9):1748-1756 8. Zhu SY, Yu KD*. Breast Cancer Vaccines: Disappointing or Promising? Front Immunol. 2022 Jan 28;13:828386. 9. Chen YY, Ge JY, Zhu SY, Shao ZM, Yu KD*. Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis. Nat Commun. 2022 Feb 10;13(1):791 10. Zhu SY, Ma D, Ye FG, Shao ZM, Yu KD*. Homologous recombination deficiency and glycolysis-related pathway in adjuvant chemotherapy for triple-negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial. Clin Transl Med. 2021;11(9):e513. 11. Ge J, Zuo W, Chen Y, Shao Z, Yu K*. The advance of adjuvant treatment for triple-negative breast cancer. Cancer Biol Med. 2021:j.issn.2095-3941.2020.0752. 12. Zhu SY, Ma D, Shao ZM, Yu KD*. Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial. Front Mol Biosci. 2021;8:752154 13. Yu KD*, Liu XY, Chen L, Mo M, Wu J, Liu GY, Di GH, Verschraegen C, Stover DG, Zhuang ZG, Bertucci F, Orlandi A, Wang J, Lippi G, Wu KJ, Osman MA, Fan L, Shao ZM. Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. Lancet Reg Health West Pac. 2021;11:100158 14. Yu KD*, Cai YW, Wu SY, Shui RH, Shao ZM. Estrogen receptor-low breast cancer: Biology chaos and treatment paradox. Cancer Commun. 2021. doi: 10.1002/cac2.12191. 15. Yu KD*, Ge JY, Liu XY, Mo M, He M, Shao ZM*. Cyclophosphamide-free Adjuvant Chemotherapy for Ovarian Protection in Young Women with Breast Cancer: a Randomized Phase 3 Trial. J Natl Cancer Inst. 2021;113(10):1352-59. 16. Zhou JQ, Zhu SY, He Y, Yu KD*. Association Between a Tri-allelic Polymorphism in the Estrogen Metabolism Oxidoreductase NRH:Quinone Oxidoreductase 2 Gene and Risk of Breast Cancer by Molecular Subtype. Front Genet. 2021,12:658285. 17. Yu KD*, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM: Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2020, 6(9):1390-1396. 18. Yu KD*, Wang X, Chen WK, Fan L, Mo M, Chen H: Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer. NPJ Precis Oncol 2020, 4:23. 19. Ma D, Chen SY, Ren JX, Pei YC, Jiang CW, Zhao S, Xiao Y, Xu XE, Liu GY, Hu X, Liang XZ, Yu KD*, Li DQ*, Jiang YZ*, Shao ZM*: Molecular features and functional implications of germline variants in triple-negative breast cancer. J Natl Cancer Inst. 2021;113(7):884-892. 20. Liang Q, Ma D, Gao RF, Yu KD*: Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes. Sci Rep 2020, 10(1):7648. 21. Li J#, Yu K#, Pang D, Wang C, Jiang J, Yang S, Liu Y, Fu P, Sheng Y, Zhang G, Cao Y, He Q, Cui S, Wang X, Ren G, Li X, Yu S, Liu P, Qu X, Tang J, Wang O, Fan Z, Jiang G, Zhang J, Wang J, Zhang H, Wang S, Zhang J, Jin F, Rao N, Ma B, He P, Xu B, Zhuang Z, Wang J, Sun Q, Guo X, Mo M, Shao Z*, Group CS: Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. J Clin Oncol 2020, 38(16):1774-1784. 22. Jiang YZ, Ge LP, Jin X, Fan L, He M, Liu Y, Chen L, Zuo WJ, Wu J, Liu GY, Di GH, Wang ZH, Yu KD*, Shao ZM*: Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations. Breast Cancer Res Treat 2020. 23. Chen YY, Ge JY, Ma D, Yu KD*: Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer. Front Oncol 2020, 10:570981. 24. Chen H, Shao ZM, Yu KD*, Xu GZ*: Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer. Ann Transl Med 2020, 8(6):342. 25. Chen H, Mo M, Liu GY, Gong YM, Yu KD*, Xu GZ*: Interaction of two functional genetic variants LOXL1 rs1048661 and VEGFA rs3025039 on the risk of age-related macular degeneration in Chinese women. Ann Transl Med 2020, 8(13):818. 26. Yu KD*, Wu SY#, Liu GY, Wu J, Di GH, Hu Z, Hou YF, Chen CM, Fan L, Tang LC, Shen ZZ, Wu KJ, Zhuang ZG, Zhang HW, Shao ZM: Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial. Cancer 2019, 125(13):2185-2193. 27. Yu KD, Shao ZM: Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up. J Clin Oncol 2019, 37(17):1515-1516. 28. Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, Ruan M, Wang H, Zhao J, Li Q, Wang P, Shi L, Yang WT, Huang W, Hu X, Yu KD*, Huang S, Bertucci F, Jiang YZ, Shao ZM*, Group AMEBCC: Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clin Cancer Res 2019, 25(16):5002-5014. 29. Jin X, Xu XE, Jiang YZ, Liu YR, Sun W, Guo YJ, Ren YX, Zuo WJ, Hu X, Huang SL, Shen HJ, Lan F, He YF, Hu GH, Di GH, He XH, Li DQ, Liu S, Yu KD*, Shao ZM*: The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Sci Adv 2019, 5(3):eaat9820. 30. Hao S, Zhao YY, Peng JJ, Ren F, Yang WT, Yu KD*, Shao ZM*: Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis. Sci Rep 2019, 9(1):286. 31. Gong DH, Chen YY, Ma D, Chen HY, Ding KF, Yu KD*: Complicated prognostic values of CCL28 in breast cancer by subtype. J Thorac Dis 2019, 11(3):777-787. 32. Fan L, Zhou P, Hong Q, Chen AX, Liu GY, Yu KD*, Shao ZM*: Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation. Oncoimmunology 2019, 8(6):e1593801. 33. Li S, Lang GT, Zhang YZ, Yu KD*, Shao ZM*, Zhang Q: Interaction between glutathione S-transferase M1-null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer. Cancer Med 2018, 7(9):4202-4207. 34. Li DD, Yang C, Shao ZM, Yu KD*: Effect of functional genetic variants in chemokine decoy receptors on the recurrence risk of breast cancer. Cancer Med 2018, 7(11):5497-5504. 35. Zuo WJ, Jiang YZ, Wang YJ, Xu XE, Hu X, Liu GY, Wu J, Di GH, Yu KD*, Shao ZM*: Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. Clin Cancer Res 2016, 22(19):4859-4869. 36. Liu YR, Jiang YZ, Xu XE, Hu X, Yu KD*, Shao ZM*: Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clin Cancer Res 2016, 22(7):1653-1662. 37. Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu KD*, Shao ZM*: Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Res 2016, 76(8):2105-2114. 38. Yu KD*, Jiang YZ, Hao S, Shao ZM: Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. BMC Med 2015, 13:254. 39. Jiang YZ#, Yu KD#, Zuo WJ#, Peng WT, Shao ZM*. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival. Cancer. 2014;120(9):1329-1337 40. Jiang YZ, Yu KD*, Peng WT, Di GH, Wu J, Liu GY, Shao ZM*. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat Commun. 2014;5:3802 41. Bao J, Yu KD*, Jiang YZ, Shao ZM, Di GH*. The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study. PLoS One. 2014;9(4):e94815 42. Jiang YZ, Yu KD*, Bao J, Peng WT, Shao ZM*. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. Cancer Res. 2014;74(13):3399-3407 43. Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA*, Shao ZM*, Symmans WF*, Chang JC*. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 2013;19(10):2723-2733 44. Yu KD#, Liu GY#, Chen CM#, Li JW, Wu J, Lu JS, Shen ZZ, Shao ZM*. Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule. Oncologist. 2013;18(5):511-517 45. Yu KD#, Huang S#, Zhang JX#, Liu GY, Shao ZM*. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:240 46. Yang C, Yu KD*, Xu WH, Chen AX, Fan L, Ou ZL, Shao ZM*. Effect of genetic variants in two chemokine decoy receptor genes, DARC and CCBP2, on metastatic potential of breast cancer. PLoS One. 2013;8(11):e78901 47. Jiang YZ, Liu YR, Yu KD*, Zuo WJ, Shao ZM*. Immediate postmastectomy breast reconstruction showed limited advantage in patient survival after stratifying by family income. PLoS One. 2013;8(12):e82807 48. Yu KD, Zhou Y, Liu GY, Li B, He PQ, Zhang HW, Lou LH, Wang XJ, Wang S, Tang JH, Liu YH, Wang X, Jiang ZF, Ma LW, Gu L, Cao MZ, Zhang QY, Wang SM, Su FX, Zheng H, Li HY, Tang LL, Sun SR, Liu JP, Shao ZM, Shen ZZ*. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat. 2012;134(1):307-313 49. Yu KD*, Wu J, Shen ZZ, Shao ZM*. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab. 2012;97(12):E2201-2209 50. Yu KD#, Liu GY#, Zhou XY#, Zhou Y, Wu J, Chen CM, Shen ZZ, Shao ZM*. Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer. Oncologist. 2012;17(6):792-800 51. Yu KD* #, Jiang YZ#, Chen S#, Cao ZG, Wu J, Shen ZZ, Shao ZM*. Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc. 2012;87(12):1171-1180 52. Yu KD#, Huang AJ#, Fan L, Li WF, Shao ZM*. Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. Cancer Res. 2012;72(2):408-419